XTNT Xtant Medical Holdings

Xtant Medical to Issue Third Quarter 2018 Results on November 14, 2018

Xtant Medical to Issue Third Quarter 2018 Results on November 14, 2018

BELGRADE, MT, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarter and year to date ended September 30, 2018, after the close of the financial markets on Wednesday, November 14, 2018.

Michael Mainelli, Interim Chief Executive Officer, and Kathie Lenzen, Senior Vice President, Finance and Administration and Chief Financial Officer, will host a conference call on Wednesday, November 14 at 4:30 PM ET to review results.

Conference Details

Conference Date: Wednesday, November 14, 2018 4:30 PM ET

Conference dial-in: 877-407-6184

International dial-in: 201-389-0877

Conference Call Name: Xtant Medical’s Third Quarter 2018 Results Call

Webcast Registration:

Following the live call, a replay will be available on the Company’s website, , under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit .

Investor Relations Contact

David Carey

Lazar Partners Ltd.

Ph: 212-867-1762

Email:

Company Contact

Kathie Lenzen, Senior Vice President, Finance & Administration and Chief Financial Officer

406.388.0480

EN
12/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xtant Medical Holdings

 PRESS RELEASE

Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chro...

Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™. “The launches of SimpliGraft and SimpliMax highlights the strength of our newly revitalized Research and Development team,” said Sean Browne, President and CEO of Xtant Medical. “...

 PRESS RELEASE

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. “2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% year-over-year, on whic...

 PRESS RELEASE

Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Res...

Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024 BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a...

 PRESS RELEASE

Xtant Medical Increases Revolving Credit Facility to $17 Million with ...

Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial BELGRADE, Mont., March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company’s revolving credit agreement with MidCap Financial Trust (“MidCap”) was amended to increase the commitment from $8.0 million to $17.0 million. The Company’s term loan was also amended to provide for an additional $10.0 million tranche, to be made available for acqui...

 PRESS RELEASE

Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Confer...

Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference BELGRADE, Mont., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference, to be held on Monday, March 4, 2024 at 12:50 p.m. Eastern Time in Boston. A live webcast of the presentation will be available on the Investors section of the Company’s website or through ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch